CANCER FACT SHEET 2022
OVARIAN CANCER
ICD-10 C56

Belgian Cancer Registry

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*(1.05)^5).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

TABLE OF CONTENTS

1.1. Ovarian cancer incidence: by region

1.1.1. Ovarian cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Females																						
Belgium	0	0	1	2	7	2	6	14	24	27	44	58	92	110	113	99	82	52	17	3	753	12.1
	[0.0]	[0.0]	[0.3]	[0.6]	[2.1]	[0.6]	[1.6]	[3.8]	[6.3]	[7.4]	[11.4]	[14.5]	[24.4]	[33.1]	[38.3]	[42.8]	[46.0]	[38.6]	[24.5]	[14.6]	[12.8]	(11.3; 13.0)
Brussels	0	0	0	0	2	1	0	0	5	4	1	2	8	8	13	8	6	3	1	1	63	12.6
	[0.0]	[0.0]	[0.0]	[0.0]	[5.0]	[1.8]	[0.0]	[0.0]	[11.1]	[9.9]	[2.7]	[5.9]	[26.9]	[32.1]	[61.0]	[46.4]	[46.1]	[29.8]	[17.3]	[48.5]	[10.1]	(9.4; 15.7)
Flanders	0	0	0	2	4	1	2	12	11	15	32	36	62	75	62	61	50	36	12	2	475	12.8
	[0.0]	[0.0]	[0.0]	[1.1]	[2.2]	[0.5]	[0.9]	[5.7]	[5.1]	[7.3]	[14.2]	[15.1]	[27.6]	[37.9]	[35.7]	[42.7]	[44.6]	[42.3]	[28.2]	[16.6]	[14.0]	(11.6; 13.9)
Wallonia	0	0	1	0	1	0	4	2	8	8	11	20	22	27	38	30	26	13	4	0	215	10.9
	[0.0]	[0.0]	[0.9]	[0.0]	[0.9]	[0.0]	[3.4]	[1.7]	[6.9]	[6.7]	[8.8]	[15.8]	[18.0]	[24.6]	[37.9]	[42.3]	[48.9]	[32.9]	[19.0]	[0.0]	[11.5]	(9.5; 12.4)

1.2. Ovarian cancer incidence: by tumour stage

1.2.1. Ovarian cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	53 [1.8]	73 [5.2]	33 [5.2]	159 [2.7]	2.7 (2.2; 3.1)
II	6 [0.2]	11 [0.8]	13 [2.1]	30 [0.5]	0.5 (0.3; 0.7)
III	28 [1.0]	138 [9.8]	87 [13.7]	254 [4.3]	4.1 (3.6; 4.6)
IV	18 [0.6]	112 [8.0]	88 [13.9]	218 [3.7]	3.4 (3.0; 3.9)
X/NA	21 [0.7]	39 [2.8]	32 [5.0]	92 [1.6]	1.5 (1.2; 1.8)

1.2.2. Ovarian cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	58 [2.0]	81 [5.8]	33 [5.2]	172 [2.9]	2.9 (2.5; 3.3)
II	8 [0.3]	23 [1.6]	19 [3.0]	50 [0.9]	0.8 (0.6; 1.0)
III	35 [1.2]	128 [9.1]	40 [6.3]	204 [3.5]	3.4 (2.9; 3.9)
IV	10 [0.3]	45 [3.2]	23 [3.6]	78 [1.3]	1.3 (1.0; 1.6)
X/NA	15 [0.5]	96 [6.8]	138 [21.8]	249 [4.2]	3.8 (3.3; 4.3)

1.2.3. Ovarian cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	58 [2.0]	78 [5.6]	35 [5.5]	171 [2.9]	2.9 (2.4; 3.3)
II	7 [0.2]	16 [1.1]	20 [3.2]	43 [0.7]	0.7 (0.5; 0.9)
III	36 [1.2]	147 [10.5]	87 [13.7]	271 [4.6]	4.4 (3.8; 4.9)
IV	21 [0.7]	118 [8.4]	91 [14.4]	230 [3.9]	3.6 (3.2; 4.1)
X/NA	4 [0.1]	14 [1.0]	20 [3.2]	38 [0.6]	0.6 (0.4; 0.8)

1.2.4. Ovarian cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

type	grade	N[CR]				ESR2013 (95%CI)
		15-54	55-74	75+	All ages	
Serous carcinoma		53 [1.8]	245 [17.5]	163 [25.7]	461 [7.8]	7.4 (6.7; 8.1)
	Low-grade	10 [0.3]	22 [1.6]	9 [1.4]	41 [0.7]	0.7 (0.5; 0.9)
	High-grade	43 [1.5]	221 [15.7]	151 [23.8]	415 [7.1]	6.7 (6.0; 7.3)
	Unspecified	0 [0.0]	2 [0.1]	3 [0.5]	5 [0.1]	0.1 (0.0; 0.1)
Mucinous carcinoma		20 [0.7]	23 [1.6]	12 [1.9]	55 [0.9]	0.9 (0.7; 1.2)
Endometrioid carcinoma		15 [0.5]	25 [1.8]	14 [2.2]	54 [0.9]	0.9 (0.7; 1.1)
Clear-cell carcinoma		10 [0.3]	21 [1.5]	4 [0.6]	35 [0.6]	0.6 (0.4; 0.8)
Adenocarcinoma		3 [0.1]	11 [0.8]	18 [2.8]	32 [0.5]	0.5 (0.3; 0.7)
Other and unspecified		25 [0.9]	48 [3.4]	42 [6.6]	116 [2.0]	1.8 (1.5; 2.2)

1.2.5. Ovarian cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

type	grade	Stage	N[CR] 15-54	55-74	75+	All ages	ESR2013 (95%CI)
Serous carcinoma		I	6 [0.2]	20 [1.4]	12 [1.9]	38 [0.6]	0.6 (0.4; 0.8)
		II	3 [0.1]	9 [0.6]	9 [1.4]	21 [0.4]	0.3 (0.2; 0.5)
		III	28 [1.0]	117 [8.3]	69 [10.9]	214 [3.6]	3.5 (3.0; 3.9)
		IV	16 [0.6]	95 [6.8]	59 [9.3]	170 [2.9]	2.7 (2.3; 3.2)
		X/NA	0 [0.0]	4 [0.3]	14 [2.2]	18 [0.3]	0.3 (0.1; 0.4)
	Low-grade	I	2 [0.1]	4 [0.3]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)
		II	1 [0.0]	2 [0.1]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)
		III	4 [0.1]	8 [0.6]	2 [0.3]	14 [0.2]	0.2 (0.1; 0.4)
		IV	3 [0.1]	8 [0.6]	4 [0.6]	15 [0.3]	0.2 (0.1; 0.4)
		X/NA	0 [0.0]	0 [0.0]	2 [0.3]	2 [0.0]	0.0 (0.0; 0.1)
	High-grade	I	4 [0.1]	16 [1.1]	11 [1.7]	31 [0.5]	0.5 (0.3; 0.7)
		II	2 [0.1]	7 [0.5]	9 [1.4]	18 [0.3]	0.3 (0.2; 0.4)
		III	24 [0.8]	109 [7.8]	67 [10.6]	200 [3.4]	3.2 (2.8; 3.7)
		IV	13 [0.4]	87 [6.2]	55 [8.7]	155 [2.6]	2.5 (2.1; 2.9)
		X/NA	0 [0.0]	2 [0.1]	9 [1.4]	11 [0.2]	0.2 (0.1; 0.3)
	Unspecified	I	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		X/NA	0 [0.0]	2 [0.1]	3 [0.5]	5 [0.1]	0.1 (0.0; 0.1)
Mucinous carcinoma		I	15 [0.5]	14 [1.0]	5 [0.8]	34 [0.6]	0.6 (0.4; 0.8)
		II	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)

type	grade	Stage	15-54	55-74	75+	All ages	ESR2013 (95%CI)
			N[CR]				ESR2013 (95%CI)
		III	2 [0.1]	3 [0.2]	2 [0.3]	7 [0.1]	0.1 (0.0; 0.2)
		IV	3 [0.1]	3 [0.2]	3 [0.5]	9 [0.2]	0.1 (0.1; 0.2)
		X/NA	0 [0.0]	1 [0.1]	2 [0.3]	3 [0.1]	0.0 (0.0; 0.1)
Endometrioid carcinoma		I	13 [0.4]	16 [1.1]	6 [0.9]	35 [0.6]	0.6 (0.4; 0.8)
		II	1 [0.0]	1 [0.1]	7 [1.1]	9 [0.2]	0.1 (0.0; 0.2)
		III	1 [0.0]	4 [0.3]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)
		IV	0 [0.0]	4 [0.3]	0 [0.0]	4 [0.1]	0.1 (0.0; 0.1)
		X/NA	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Clear-cell carcinoma		I	5 [0.2]	11 [0.8]	1 [0.2]	17 [0.3]	0.3 (0.1; 0.4)
		II	3 [0.1]	1 [0.1]	1 [0.2]	5 [0.1]	0.1 (0.0; 0.2)
		III	2 [0.1]	6 [0.4]	2 [0.3]	10 [0.2]	0.2 (0.1; 0.3)
		IV	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
		X/NA	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
Adenocarcinoma		I	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
		II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
		III	0 [0.0]	2 [0.1]	3 [0.5]	5 [0.1]	0.1 (0.0; 0.1)
		IV	1 [0.0]	6 [0.4]	14 [2.2]	21 [0.4]	0.3 (0.2; 0.4)
		X/NA	2 [0.1]	2 [0.1]	1 [0.2]	5 [0.1]	0.1 (0.0; 0.2)
Other and unspecified		I	19 [0.7]	16 [1.1]	11 [1.7]	46 [0.8]	0.8 (0.5; 1.0)
		II	0 [0.0]	3 [0.2]	3 [0.5]	6 [0.1]	0.1 (0.0; 0.2)
		III	3 [0.1]	15 [1.1]	10 [1.6]	29 [0.5]	0.5 (0.3; 0.6)
		IV	1 [0.0]	8 [0.6]	15 [2.4]	24 [0.4]	0.3 (0.2; 0.5)
		X/NA	2 [0.1]	6 [0.4]	3 [0.5]	11 [0.2]	0.2 (0.1; 0.3)

Belgian Cancer Registry

2.1. Ovarian cancer incidence trends: by region

2.1.1. Ovarian cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
Belgium	**N**	911	931	921	923	876	784	861	830	800	775	836	802	733	770	741	713	811	803	753		
	CR	17.2	17.5	17.2	17.1	16.1	14.3	15.6	14.9	14.2	13.7	14.7	14.1	12.8	13.4	12.8	12.3	13.9	13.7	12.8		
	ESR2013	17.8	17.7	17.6	17.4	16.2	14.3	15.6	14.9	14.2	13.6	14.5	13.9	12.5	13.1	12.4	11.8	13.4	13.1	12.1	-2.2 (-2.6; -1.8)	2004-2022
																					-3.2 (-4.2; -2.1)	2004-2012
																					-1.4 (-2.3; -0.6)	2013-2022
Brussels	**N**	73	87	63	77	78	62	77	75	64	48	75	60	61	60	61	56	75	87	63		
	CR	14.1	16.6	11.9	14.4	14.4	11.2	13.7	13.0	10.9	8.1	12.6	10.0	10.0	9.8	10.0	9.1	12.1	14.0	10.1		
	ESR2013	16.2	18.7	13.9	16.0	16.2	13.8	15.9	15.0	12.6	9.5	14.8	12.7	11.9	12.2	12.1	10.9	15.1	16.7	12.6	-1.4 (-2.7; 0.0)	2004-2022
Flanders	**N**	562	557	581	544	534	476	506	506	483	473	485	491	442	475	459	439	487	472	475		
	CR	18.4	18.2	18.9	17.5	17.1	15.1	16.0	15.8	15.0	14.6	14.9	15.1	13.5	14.4	13.9	13.2	14.5	14.0	14.0		
	ESR2013	18.8	18.1	18.8	17.4	16.7	14.7	15.5	15.3	14.5	14.0	14.1	14.3	12.7	13.4	12.9	12.1	13.3	12.7	12.8	-2.3 (-2.7; -2.0)	2004-2022
																					-3.4 (-4.2; -2.7)	2004-2013
																					-1.2 (-2.0; -0.5)	2014-2022
Wallonia	**N**	276	287	277	302	264	246	278	249	253	254	276	251	230	235	221	218	249	244	215		
	CR	15.9	16.4	15.8	17.1	14.8	13.8	15.5	13.7	13.9	13.9	15.0	13.6	12.5	12.7	11.9	11.7	13.4	13.1	11.5		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
ESR2013	16.4	17.0	16.3	17.6	15.3	13.8	15.9	13.8	14.1	14.1	15.2	13.5	12.2	12.6	11.5	11.3	13.2	12.7	10.9	-2.2 (-2.8; -1.6)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Ovarian cancer incidence trends: by tumour stage

2.2.1. Ovarian cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage		2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
I	N	151	146	160	185	171		
	CR	2.6	2.5	2.7	3.2	2.9		
	ESR2013	2.6	2.5	2.7	3.1	2.9	0.4 (-0.7; 1.5)	2004-2022
II	N	44	37	49	51	43		
	CR	0.8	0.6	0.8	0.9	0.7		
	ESR2013	0.8	0.6	0.8	0.8	0.7	-1.3 (-3.0; 0.4)	2004-2022
III	N	260	218	244	250	271		
	CR	4.5	3.8	4.2	4.3	4.6		
	ESR2013	4.4	3.6	4.0	4.1	4.4	0.0 (-0.8; 0.8)	2004-2022
IV	N	205	228	264	273	230		
	CR	3.5	3.9	4.5	4.7	3.9		
	ESR2013	3.4	3.7	4.3	4.5	3.6	2.6 (1.6; 3.6)	2004-2022
X/NA	N	81	84	94	44	38		
	CR	1.4	1.4	1.6	0.8	0.6		
	ESR2013	1.3	1.3	1.4	0.7	0.6	-12.7 (-14.4; -10.9)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Ovarian cancer incidence trends: by age group

2.3.1. Ovarian cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, %	(95%CI)	Period
15-54	N	209	228	201	219	185	162	175	157	188	160	156	154	155	144	150	142	130	154	126			
	CR	7.4	8.1	7.1	7.7	6.5	5.6	6.1	5.4	6.5	5.5	5.4	5.3	5.3	5.0	5.2	4.9	4.5	5.3	4.3			
	ESR2013	7.7	8.2	7.2	7.8	6.5	5.7	6.1	5.4	6.4	5.5	5.3	5.3	5.3	5.0	5.2	4.9	4.5	5.4	4.5	-2.9	(-3.5; -2.2)	2004-2022
																					-4.2	(-5.5; -2.8)	2004-2013
																					-1.5	(-2.9; -0.1)	2014-2022
55-74	N	459	419	459	446	424	376	423	382	371	369	393	385	340	385	335	331	387	377	373			
	CR	41.9	38.0	41.4	39.9	37.6	33.0	36.6	32.5	31.1	30.4	32.0	30.8	26.7	29.5	25.2	24.4	28.1	27.0	26.6			
	ESR2013	42.0	37.6	41.4	40.1	37.7	33.2	36.8	32.9	31.5	30.8	32.6	31.6	27.2	30.1	25.4	24.7	28.3	27.2	26.7	-2.7	(-3.2; -2.2)	2004-2022
75+	N	242	281	261	252	266	241	263	282	239	244	285	261	235	240	252	237	292	268	253			
	CR	46.6	52.9	47.9	45.2	46.7	41.7	44.8	47.5	39.8	40.4	46.7	42.3	38.1	39.2	41.2	38.6	47.1	43.3	39.9			
	ESR2013	46.0	52.8	47.5	44.6	46.0	40.7	44.4	47.9	40.0	40.5	47.1	42.7	38.6	39.6	41.7	38.5	49.6	44.6	40.8	-0.7	(-1.4; 0.0)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Ovarian cancer prevalence: by region

3.1.1. Ovarian cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022

Region		Females			
		1-year	5-year	10-year	15-year
Belgium	N	645	2,353	3,626	4,639
	CR	10.9	39.6	61.1	78
	ESR2013	10.4	38.0	58.5	74.6
Brussels	N	59	218	321	412
	CR	9.3	34.4	50.7	65.1
	ESR2013	11.7	42.0	62.1	79.2
Flanders	N	403	1,441	2,226	2,863
	CR	11.8	42.1	65.0	83.7
	ESR2013	10.8	39.0	60.0	76.8
Wallonia	N	183	694	1,079	1,364
	CR	9.7	36.9	57.4	72.5
	ESR2013	9.3	35.2	54.7	69.1

4.1. Ovarian cancer survival: by region

4.1.1. Ovarian cancer survival by region and age group: number at risk and net survival probabilities, 2013-2022

Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
			Net Survival Probability, 2013-2022			
Females						
Belgium	**All ages**	7,678	78.5% (77.5%; 79.5%)	57.9% (56.7%; 59.1%)	45.5% (44.2%; 46.9%)	34.7% (32.5%; 36.9%)
	15-54	1,318	92.9% (91.6%; 94.4%)	80.2% (78.0%; 82.5%)	70.7% (68.1%; 73.5%)	59.9% (56.6%; 63.5%)
	55-74	3,658	86.8% (85.6%; 87.9%)	64.4% (62.8%; 66.1%)	48.6% (46.7%; 50.5%)	35.1% (32.6%; 37.7%)
	75+	2,558	58.6% (56.6%; 60.7%)	36.5% (34.4%; 38.8%)	27.1% (24.8%; 29.7%)	19.8% (15.3%; 25.6%)
Brussels	**All ages**	637	81.6% (78.5%; 84.9%)	63.4% (59.3%; 67.8%)	49.0% (44.3%; 54.3%)	28.6% (18.9%; 43.5%)
	15-54	163	93.8% (90.1%; 97.7%)	81.4% (75.2%; 88.0%)	68.8% (60.9%; 77.7%)	54.4% (42.9%; 69.0%)
	55-74	277	84.5% (80.2%; 89.0%)	65.6% (59.8%; 72.0%)	46.9% (40.3%; 54.5%)	30.5% (22.5%; 41.5%)
	75+	187	66.5% (59.5%; 74.3%)	44.3% (36.4%; 53.9%)	34.1% (25.4%; 45.7%)	12.8% (3.7%; 44.8%)
Flanders	**All ages**	4,664	78.5% (77.2%; 79.7%)	58.4% (56.8%; 60.0%)	46.4% (44.6%; 48.2%)	36.6% (33.9%; 39.4%)
	15-54	712	93.5% (91.7%; 95.4%)	80.4% (77.4%; 83.5%)	72.2% (68.7%; 75.8%)	61.8% (57.5%; 66.5%)
	55-74	2,226	87.3% (85.9%; 88.8%)	65.5% (63.4%; 67.7%)	50.2% (47.8%; 52.7%)	37.0% (33.8%; 40.5%)
	75+	1,622	58.9% (56.4%; 61.5%)	38.4% (35.7%; 41.4%)	28.8% (25.8%; 32.2%)	23.3% (18.0%; 30.3%)
Wallonia	**All ages**	2,377	77.7% (76.0%; 79.5%)	55.5% (53.3%; 57.7%)	42.9% (40.5%; 45.3%)	32.2% (29.3%; 35.5%)
	15-54	443	91.7% (89.1%; 94.3%)	79.5% (75.7%; 83.5%)	68.9% (64.3%; 73.8%)	58.0% (52.3%; 64.4%)

			Net Survival Probability, 2013-2022			
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	55-74	1,155	86.2% (84.2%; 88.3%)	62.0% (59.0%; 65.0%)	45.9% (42.7%; 49.3%)	32.4% (28.4%; 36.8%)
	75+	749	56.0% (52.3%; 59.9%)	30.5% (26.9%; 34.6%)	21.7% (17.9%; 26.2%)	16.0% (10.6%; 24.3%)

4.2. Ovarian cancer survival: by tumour type and tumour stage

4.2.1. Ovarian cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2013-2022

type	grade	cStage	N at risk	Net Survival Probability, 2013-2022					
				1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Ovary		All	7,678	78.5% (77.5%; 79.5%)	67.2% (66.1%; 68.3%)	57.9% (56.7%; 59.1%)	50.9% (49.6%; 52.2%)	45.5% (44.2%; 46.9%)	34.7% (32.5%; 36.9%)
		I	864	96.6% (95.1%; 98.2%)	95.1% (93.1%; 97.1%)	93.7% (91.1%; 96.2%)	89.8% (86.4%; 93.3%)	87.8% (83.8%; 92.0%)	90.9% (81.4%; 101.5%)
		II	221	83.9% (78.8%; 89.3%)	78.1% (72.1%; 84.5%)	75.1% (68.6%; 82.3%)	73.3% (66.0%; 81.4%)	66.4% (57.9%; 76.2%)	38.7% (24.2%; 61.7%)
		III	1,850	79.4% (77.5%; 81.4%)	64.7% (62.4%; 67.1%)	52.7% (50.2%; 55.3%)	42.2% (39.6%; 45.0%)	34.9% (32.2%; 37.8%)	20.7% (17.0%; 25.3%)
		IV	1,938	64.7% (62.6%; 67.0%)	46.9% (44.6%; 49.3%)	32.6% (30.4%; 35.0%)	24.5% (22.3%; 26.8%)	18.1% (16.1%; 20.4%)	8.8% (6.6%; 11.6%)
		X/NA	2,810	81.3% (79.8%; 82.9%)	73.4% (71.6%; 75.2%)	66.3% (64.4%; 68.3%)	60.8% (58.8%; 62.9%)	56.3% (54.2%; 58.5%)	44.8% (41.4%; 48.5%)
Serous carcinoma		All	4,843	82.1% (81.0%; 83.3%)	68.1% (66.7%; 69.6%)	56.3% (54.8%; 57.9%)	46.3% (44.7%; 47.9%)	39.2% (37.6%; 40.9%)	24.6% (22.5%; 27.0%)
		I	265	98.4% (96.2%; 100.8%)	96.0% (92.6%; 99.5%)	92.5% (87.8%; 97.4%)	84.7% (78.1%; 91.9%)	81.8% (73.8%; 90.7%)	77.8% (62.0%; 97.6%)
		II	129	92.3% (87.2%; 97.6%)	83.1% (76.2%; 90.7%)	77.3% (69.3%; 86.2%)	72.0% (62.8%; 82.5%)	62.4% (52.1%; 74.9%)	33.5% (18.1%; 62.1%)
		III	1,474	85.5% (83.6%; 87.5%)	70.3% (67.8%; 72.9%)	57.8% (55.0%; 60.8%)	45.6% (42.6%; 48.7%)	36.7% (33.6%; 40.0%)	18.1% (14.2%; 23.1%)
		IV	1,444	74.1% (71.8%; 76.5%)	54.9% (52.2%; 57.7%)	39.0% (36.3%; 41.9%)	28.9% (26.3%; 31.8%)	22.0% (19.5%; 24.8%)	10.6% (7.8%; 14.3%)
		X/NA	1,531	82.8% (80.8%; 84.8%)	72.4% (70.0%; 74.9%)	62.9% (60.3%; 65.6%)	53.9% (51.1%; 56.7%)	47.5% (44.8%; 50.5%)	32.7% (29.2%; 36.7%)
	Low-grade	All	790	83.7% (81.0%; 86.5%)	72.1% (68.8%; 75.5%)	62.6% (59.0%; 66.4%)	53.3% (49.5%; 57.4%)	44.6% (40.7%; 48.9%)	35.6% (30.5%; 41.4%)
		I	52	99.9% (96.1%; 103.8%)	97.6% (90.8%; 104.8%)	97.6% (89.5%; 106.5%)	95.3% (83.1%; 109.1%)	84.5% (65.5%; 108.9%)	102.0% (79.1%; 131.5%)
		II	27	N<50	N<50	N<50	N<50	N<50	N<50
		III	190	85.5% (80.3%; 91.1%)	71.0% (64.3%; 78.4%)	58.6% (51.4%; 66.9%)	50.8% (43.3%; 59.6%)	39.0% (31.5%; 48.2%)	33.5% (23.6%; 47.5%)
		IV	181	71.9% (65.5%; 79.0%)	49.9% (42.9%; 58.1%)	38.2% (31.3%; 46.6%)	24.8% (18.6%; 33.0%)	15.4% (10.4%; 22.9%)	9.2% (5.0%; 16.8%)
		X/NA	340	86.0% (82.2%; 90.0%)	79.7% (75.1%; 84.5%)	72.0% (66.9%; 77.5%)	62.3% (56.8%; 68.4%)	55.9% (50.2%; 62.3%)	42.9% (35.3%; 52.2%)
	High-grade	All	3,826	82.2% (80.9%; 83.5%)	67.9% (66.3%; 69.5%)	55.3% (53.5%; 57.1%)	44.8% (43.0%; 46.7%)	38.1% (36.2%; 40.1%)	21.0% (18.3%; 24.0%)

type	grade	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
				Net Survival Probability, 2013-2022					
		I	206	98.0% (95.2%; 100.8%)	95.3% (91.4%; 99.5%)	90.6% (85.1%; 96.6%)	81.6% (73.8%; 90.3%)	80.4% (71.6%; 90.3%)	75.7% (62.0%; 92.4%)
		II	99	93.8% (88.4%; 99.5%)	83.6% (75.7%; 92.4%)	80.6% (71.8%; 90.5%)	73.2% (62.6%; 85.7%)	65.9% (53.9%; 80.6%)	26.2% (10.7%; 64.1%)
		III	1,246	85.7% (83.6%; 87.8%)	70.4% (67.7%; 73.3%)	57.9% (54.9%; 61.2%)	44.7% (41.4%; 48.2%)	36.5% (33.1%; 40.2%)	15.1% (10.6%; 21.5%)
		IV	1,220	74.5% (71.9%; 77.1%)	55.9% (53.0%; 59.0%)	39.0% (36.0%; 42.2%)	29.4% (26.5%; 32.6%)	22.7% (19.9%; 25.9%)	9.6% (6.4%; 14.4%)
		X/NA	1,055	83.0% (80.6%; 85.4%)	71.9% (69.0%; 74.9%)	61.4% (58.2%; 64.7%)	52.1% (48.8%; 55.6%)	45.9% (42.6%; 49.5%)	29.4% (25.2%; 34.4%)
	Unspecified	All	227	75.2% (69.5%; 81.3%)	58.4% (52.0%; 65.6%)	51.4% (44.9%; 58.9%)	44.6% (38.1%; 52.3%)	37.9% (31.5%; 45.6%)	26.0% (19.7%; 34.3%)
		I	7	N<50	N<50	N<50	N<50	N<50	N<50
		II	3	N<50	N<50	N<50	N<50	N<50	N<50
		III	38	N<50	N<50	N<50	N<50	N<50	N<50
		IV	43	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	136	72.8% (65.3%; 81.0%)	58.2% (50.2%; 67.6%)	52.0% (43.8%; 61.7%)	46.5% (38.3%; 56.4%)	39.6% (31.6%; 49.7%)	30.0% (22.0%; 41.0%)
Mucinous carcinoma		All	543	82.3% (79.0%; 85.7%)	76.9% (73.1%; 80.9%)	74.0% (69.9%; 78.3%)	72.6% (68.3%; 77.1%)	70.3% (65.6%; 75.3%)	66.9% (60.0%; 74.5%)
		I	167	98.8% (96.1%; 101.5%)	97.2% (92.9%; 101.6%)	98.0% (93.0%; 103.2%)	96.7% (90.7%; 103.0%)	94.7% (87.3%; 102.8%)	108.9% (96.9%; 122.2%)
		II	11	N<50	N<50	N<50	N<50	N<50	N<50
		III	52	58.8% (46.7%; 74.1%)	43.6% (31.6%; 60.0%)	35.2% (23.7%; 52.3%)	32.5% (20.9%; 50.5%)	33.2% (21.4%; 51.7%)	30.4% (18.0%; 51.3%)
		IV	58	35.5% (25.1%; 50.2%)	23.2% (14.5%; 37.3%)	11.5% (5.6%; 23.8%)	9.7% (4.4%; 21.6%)	7.2% (2.7%; 18.7%)	FU<10y
		X/NA	255	86.8% (82.6%; 91.3%)	83.0% (78.2%; 88.1%)	80.9% (75.8%; 86.4%)	79.6% (74.1%; 85.5%)	76.6% (70.5%; 83.2%)	70.7% (62.0%; 80.7%)
Endometrioid carcinoma		All	517	94.3% (92.0%; 96.7%)	90.8% (87.8%; 93.9%)	89.1% (85.6%; 92.8%)	86.1% (82.0%; 90.5%)	83.8% (79.1%; 88.7%)	80.5% (66.5%; 97.3%)
		I	150	100.8% (98.9%; 102.7%)	98.8% (94.8%; 102.9%)	100.4% (95.8%; 105.3%)	100.9% (94.3%; 108.0%)	101.4% (93.8%; 109.6%)	123.3% (108.9%; 139.5%)
		II	23	N<50	N<50	N<50	N<50	N<50	N<50
		III	50	81.9% (71.3%; 94.1%)	77.3% (65.3%; 91.4%)	68.8% (55.4%; 85.4%)	53.3% (39.2%; 72.5%)	51.5% (37.2%; 71.1%)	FU<10y
		IV	30	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	264	95.3% (92.4%; 98.4%)	91.7% (87.8%; 95.8%)	89.5% (84.9%; 94.3%)	87.8% (82.7%; 93.1%)	86.3% (80.5%; 92.4%)	79.7% (62.5%; 101.6%)

type	grade	cStage	N at risk	Net Survival Probability, 2013-2022					
				1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Clear-cell carcinoma		All	353	87.1% (83.4%; 90.9%)	80.4% (76.1%; 85.1%)	74.0% (69.0%; 79.3%)	73.3% (68.0%; 78.9%)	69.5% (63.7%; 75.8%)	61.5% (50.8%; 74.5%)
		I	104	97.3% (93.6%; 101.0%)	95.6% (90.9%; 100.7%)	96.0% (90.8%; 101.5%)	94.6% (88.1%; 101.6%)	87.2% (77.1%; 98.7%)	80.3% (63.2%; 101.9%)
		II	12	N<50	N<50	N<50	N<50	N<50	N<50
		III	41	N<50	N<50	N<50	N<50	N<50	N<50
		IV	33	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	163	92.3% (87.9%; 96.9%)	88.1% (82.6%; 94.0%)	80.1% (73.3%; 87.5%)	79.9% (72.7%; 87.7%)	79.2% (71.6%; 87.5%)	68.9% (54.1%; 87.9%)
Adenocarcinoma		All	318	36.2% (31.1%; 42.0%)	27.7% (23.0%; 33.4%)	20.9% (16.5%; 26.4%)	18.1% (13.8%; 23.6%)	13.2% (9.4%; 18.4%)	10.3% (6.4%; 16.7%)
		I	7	N<50	N<50	N<50	N<50	N<50	N<50
		II	1	N<50	N<50	N<50	N<50	N<50	N<50
		III	55	37.5% (26.5%; 53.1%)	29.2% (19.1%; 44.7%)	17.9% (9.8%; 33.0%)	15.6% (7.9%; 30.8%)	12.8% (5.8%; 28.0%)	13.1% (6.0%; 28.8%)
		IV	172	32.3% (25.9%; 40.3%)	22.0% (16.4%; 29.5%)	11.7% (7.4%; 18.5%)	8.5% (4.8%; 14.9%)	2.1% (0.6%; 6.9%)	FU<10y
		X/NA	83	38.5% (29.1%; 50.9%)	32.8% (23.7%; 45.5%)	33.9% (24.4%; 46.9%)	31.2% (21.8%; 44.6%)	27.1% (18.1%; 40.6%)	18.2% (9.2%; 36.2%)
Other and unspecified		All	1,114	62.8% (59.9%; 65.8%)	54.5% (51.4%; 57.7%)	48.0% (44.9%; 51.4%)	47.0% (43.7%; 50.5%)	45.7% (42.2%; 49.5%)	41.4% (35.4%; 48.5%)
		I	171	88.2% (83.1%; 93.7%)	88.3% (82.8%; 94.2%)	84.2% (77.2%; 91.9%)	78.9% (70.4%; 88.5%)	79.1% (70.0%; 89.3%)	65.9% (38.0%; 114.3%)
		II	45	N<50	N<50	N<50	N<50	N<50	N<50
		III	178	46.8% (39.8%; 55.0%)	33.3% (26.7%; 41.6%)	22.4% (16.5%; 30.5%)	21.4% (15.3%; 29.9%)	23.5% (16.8%; 32.8%)	39.6% (27.7%; 56.7%)
		IV	201	36.2% (30.0%; 43.6%)	19.5% (14.5%; 26.2%)	11.0% (7.2%; 16.8%)	9.9% (6.2%; 15.6%)	7.4% (4.2%; 13.0%)	FU<10y
		X/NA	519	70.8% (66.8%; 75.0%)	63.9% (59.6%; 68.5%)	58.5% (54.0%; 63.4%)	58.1% (53.4%; 63.2%)	56.1% (51.1%; 61.6%)	49.6% (41.8%; 58.9%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.2. Ovarian cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2013-2022

type	grade	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Net Survival Probability, 2013-2022									
Ovary		All	7,678	78.5% (77.5%; 79.5%)	67.2% (66.1%; 68.3%)	57.9% (56.7%; 59.1%)	50.9% (49.6%; 52.2%)	45.5% (44.2%; 46.9%)	34.7% (32.5%; 36.9%)
		I	1,561	98.7% (97.9%; 99.6%)	96.9% (95.7%; 98.2%)	94.9% (93.2%; 96.6%)	92.9% (90.8%; 95.0%)	92.2% (89.8%; 94.6%)	88.5% (82.2%; 95.3%)
		II	464	91.8% (89.1%; 94.6%)	84.8% (81.2%; 88.6%)	79.7% (75.5%; 84.2%)	74.7% (69.9%; 79.9%)	69.7% (64.2%; 75.6%)	47.5% (36.2%; 62.2%)
		III	2,153	92.0% (90.8%; 93.3%)	79.1% (77.2%; 81.0%)	65.7% (63.4%; 67.9%)	54.1% (51.7%; 56.6%)	45.6% (43.1%; 48.3%)	25.6% (22.4%; 29.3%)
		IV	875	77.0% (74.1%; 80.0%)	60.3% (56.9%; 63.8%)	44.4% (40.9%; 48.1%)	35.1% (31.7%; 38.9%)	24.8% (21.5%; 28.5%)	15.1% (11.6%; 19.6%)
		X/NA	2,632	53.5% (51.6%; 55.5%)	38.9% (37.0%; 41.0%)	30.4% (28.5%; 32.4%)	24.8% (23.0%; 26.8%)	21.1% (19.3%; 23.1%)	15.8% (13.4%; 18.7%)
Serous carcinoma		All	4,843	82.1% (81.0%; 83.3%)	68.1% (66.7%; 69.6%)	56.3% (54.8%; 57.9%)	46.3% (44.7%; 47.9%)	39.2% (37.6%; 40.9%)	24.6% (22.5%; 27.0%)
		I	447	98.5% (96.7%; 100.2%)	95.1% (92.4%; 97.9%)	90.7% (87.0%; 94.5%)	86.2% (81.8%; 90.9%)	84.3% (79.2%; 89.8%)	80.1% (70.9%; 90.5%)
		II	269	95.0% (92.0%; 98.2%)	89.8% (85.5%; 94.2%)	85.1% (80.0%; 90.6%)	77.4% (71.2%; 84.1%)	72.3% (65.3%; 79.9%)	50.1% (36.9%; 67.8%)
		III	1,814	94.7% (93.6%; 95.9%)	82.3% (80.3%; 84.2%)	68.6% (66.3%; 71.1%)	55.4% (52.8%; 58.2%)	46.5% (43.7%; 49.4%)	23.8% (20.5%; 27.7%)
		IV	703	83.0% (80.1%; 85.9%)	66.3% (62.7%; 70.1%)	49.8% (45.9%; 54.1%)	39.2% (35.2%; 43.6%)	27.6% (23.8%; 32.0%)	16.9% (13.0%; 22.1%)
		X/NA	1,610	60.9% (58.4%; 63.4%)	41.9% (39.4%; 44.5%)	31.0% (28.6%; 33.6%)	22.9% (20.6%; 25.4%)	18.3% (16.1%; 20.7%)	10.1% (7.6%; 13.5%)
	Low-grade	All	790	83.7% (81.0%; 86.5%)	72.1% (68.8%; 75.5%)	62.6% (59.0%; 66.4%)	53.3% (49.5%; 57.4%)	44.6% (40.7%; 48.9%)	35.6% (30.5%; 41.4%)
		I	107	99.0% (95.9%; 102.3%)	96.1% (90.9%; 101.5%)	91.6% (84.5%; 99.2%)	89.3% (80.9%; 98.5%)	87.4% (77.6%; 98.5%)	97.1% (83.6%; 112.9%)
		II	36	N<50	N<50	N<50	N<50	N<50	N<50
		III	287	97.2% (94.8%; 99.5%)	89.6% (85.6%; 93.7%)	75.4% (69.9%; 81.2%)	64.1% (58.1%; 70.8%)	54.4% (47.9%; 61.7%)	37.2% (29.0%; 47.8%)
		IV	98	83.6% (76.3%; 91.5%)	71.0% (62.3%; 81.0%)	60.2% (50.8%; 71.5%)	50.9% (41.0%; 63.3%)	31.6% (22.5%; 44.6%)	20.9% (12.0%; 36.6%)
		X/NA	262	62.3% (56.5%; 68.7%)	41.8% (35.9%; 48.6%)	35.0% (29.3%; 41.8%)	25.3% (20.2%; 31.7%)	19.2% (14.6%; 25.3%)	12.0% (6.9%; 20.8%)
	High-grade	All	3,826	82.2% (80.9%; 83.5%)	67.9% (66.3%; 69.5%)	55.3% (53.5%; 57.1%)	44.8% (43.0%; 46.7%)	38.1% (36.2%; 40.1%)	21.0% (18.3%; 24.0%)
		I	307	98.7% (96.6%; 100.8%)	95.0% (91.7%; 98.5%)	91.1% (86.7%; 95.8%)	86.5% (81.0%; 92.3%)	84.7% (78.4%; 91.4%)	76.7% (63.6%; 92.4%)
		II	217	96.4% (93.3%; 99.6%)	90.6% (85.9%; 95.6%)	85.2% (79.4%; 91.4%)	77.0% (69.9%; 84.7%)	72.9% (65.0%; 81.8%)	48.9% (32.8%; 73.0%)
		III	1,459	94.3% (92.9%; 95.6%)	81.2% (79.1%; 83.5%)	67.5% (64.8%; 70.3%)	53.7% (50.8%; 56.8%)	45.0% (41.9%; 48.3%)	20.4% (16.6%; 25.1%)

type	grade	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
				Net Survival Probability, 2013-2022					
		IV	581	83.1% (79.9%; 86.4%)	66.3% (62.3%; 70.5%)	48.4% (44.0%; 53.1%)	37.2% (32.8%; 42.1%)	27.4% (23.2%; 32.3%)	15.8% (11.6%; 21.5%)
		X/NA	1,262	61.4% (58.7%; 64.3%)	42.7% (39.9%; 45.7%)	30.5% (27.8%; 33.5%)	22.5% (19.9%; 25.4%)	18.1% (15.6%; 20.9%)	7.7% (4.9%; 12.1%)
	Unspecified	All	227	75.2% (69.5%; 81.3%)	58.4% (52.0%; 65.6%)	51.4% (44.9%; 58.9%)	44.6% (38.1%; 52.3%)	37.9% (31.5%; 45.6%)	26.0% (19.7%; 34.3%)
		I	33	N<50	N<50	N<50	N<50	N<50	N<50
		II	16	N<50	N<50	N<50	N<50	N<50	N<50
		III	68	94.4% (88.4%; 100.9%)	73.2% (62.7%; 85.3%)	63.6% (52.4%; 77.2%)	52.5% (40.9%; 67.5%)	42.5% (31.5%; 57.5%)	22.3% (13.3%; 37.3%)
		IV	24	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	86	47.7% (38.0%; 60.1%)	29.9% (21.3%; 42.0%)	24.2% (16.3%; 36.0%)	20.8% (13.3%; 32.6%)	18.1% (10.9%; 29.9%)	19.3% (11.0%; 33.7%)
Mucinous carcinoma		All	543	82.3% (79.0%; 85.7%)	76.9% (73.1%; 80.9%)	74.0% (69.9%; 78.3%)	72.6% (68.3%; 77.1%)	70.3% (65.6%; 75.3%)	66.9% (60.0%; 74.5%)
		I	336	98.1% (96.1%; 100.1%)	96.9% (94.2%; 99.7%)	97.1% (93.9%; 100.3%)	95.4% (91.6%; 99.4%)	94.4% (90.0%; 99.1%)	97.9% (91.1%; 105.1%)
		II	28	N<50	N<50	N<50	N<50	N<50	N<50
		III	52	62.5% (50.4%; 77.6%)	45.2% (33.1%; 61.6%)	36.9% (25.2%; 54.1%)	35.5% (23.8%; 53.1%)	34.1% (22.3%; 52.1%)	19.3% (8.9%; 42.2%)
		IV	27	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	100	46.6% (37.7%; 57.5%)	34.8% (26.6%; 45.7%)	34.2% (25.8%; 45.2%)	32.3% (24.0%; 43.5%)	29.2% (20.8%; 41.0%)	29.5% (20.1%; 43.3%)
Endometrioid carcinoma		All	517	94.3% (92.0%; 96.7%)	90.8% (87.8%; 93.9%)	89.1% (85.6%; 92.8%)	86.1% (82.0%; 90.5%)	83.8% (79.1%; 88.7%)	80.5% (66.5%; 97.3%)
		I	312	100.6% (99.3%; 102.0%)	98.7% (96.1%; 101.4%)	98.5% (95.2%; 101.9%)	98.0% (93.8%; 102.4%)	97.8% (92.8%; 102.9%)	96.8% (77.5%; 121.0%)
		II	64	93.9% (87.4%; 100.9%)	89.4% (80.9%; 98.9%)	89.4% (79.8%; 100.2%)	84.4% (72.7%; 98.0%)	79.8% (66.0%; 96.5%)	64.4% (36.8%; 112.6%)
		III	64	88.4% (80.4%; 97.2%)	76.0% (65.5%; 88.1%)	71.6% (60.4%; 84.8%)	59.7% (47.4%; 75.1%)	52.0% (39.6%; 68.2%)	37.7% (23.8%; 59.8%)
		IV	15	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	62	77.3% (67.0%; 89.1%)	79.5% (69.0%; 91.7%)	75.2% (63.3%; 89.4%)	70.3% (57.2%; 86.3%)	69.7% (55.9%; 87.1%)	84.8% (67.2%; 106.9%)
Clear-cell carcinoma		All	353	87.1% (83.4%; 90.9%)	80.4% (76.1%; 85.1%)	74.0% (69.0%; 79.3%)	73.3% (68.0%; 78.9%)	69.5% (63.7%; 75.8%)	61.5% (50.8%; 74.5%)
		I	197	98.8% (96.6%; 101.0%)	98.2% (95.2%; 101.2%)	94.9% (90.5%; 99.4%)	94.0% (89.0%; 99.3%)	92.7% (86.7%; 99.0%)	84.8% (70.4%; 102.2%)
		II	29	N<50	N<50	N<50	N<50	N<50	N<50

type	grade	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
				Net Survival Probability, 2013-2022					
		III	57	85.1% (75.9%; 95.4%)	57.0% (44.9%; 72.5%)	43.8% (31.7%; 60.7%)	44.6% (32.2%; 61.7%)	31.3% (19.8%; 49.5%)	20.2% (8.0%; 50.5%)
		IV	13	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	57	57.4% (45.7%; 72.0%)	53.0% (41.1%; 68.4%)	46.8% (34.9%; 62.8%)	46.1% (33.9%; 62.7%)	42.8% (30.5%; 60.1%)	45.7% (29.8%; 70.1%)
Adenocarcinoma		All	318	36.2% (31.1%; 42.0%)	27.7% (23.0%; 33.4%)	20.9% (16.5%; 26.4%)	18.1% (13.8%; 23.6%)	13.2% (9.4%; 18.4%)	10.3% (6.4%; 16.7%)
		I	11	N<50	N<50	N<50	N<50	N<50	N<50
		II	2	N<50	N<50	N<50	N<50	N<50	N<50
		III	26	N<50	N<50	N<50	N<50	N<50	N<50
		IV	57	39.4% (28.5%; 54.6%)	25.6% (16.4%; 40.1%)	16.6% (9.1%; 30.1%)	13.4% (6.8%; 26.2%)	8.3% (3.5%; 19.6%)	FU<10y
		X/NA	222	27.6% (22.2%; 34.4%)	19.3% (14.5%; 25.7%)	12.6% (8.5%; 18.7%)	9.5% (5.8%; 15.8%)	5.0% (2.4%; 10.4%)	3.5% (1.4%; 8.9%)
Other and unspecified		All	1,114	62.8% (59.9%; 65.8%)	54.5% (51.4%; 57.7%)	48.0% (44.9%; 51.4%)	47.0% (43.7%; 50.5%)	45.7% (42.2%; 49.5%)	41.4% (35.4%; 48.5%)
		I	260	97.7% (95.4%; 100.0%)	96.8% (94.0%; 99.8%)	94.8% (91.1%; 98.7%)	94.6% (90.4%; 99.0%)	96.7% (92.4%; 101.2%)	84.8% (70.5%; 102.1%)
		II	72	85.0% (76.7%; 94.2%)	69.4% (58.9%; 81.7%)	63.0% (51.8%; 76.5%)	63.1% (51.5%; 77.3%)	63.2% (51.0%; 78.2%)	53.6% (30.6%; 94.0%)
		III	140	76.0% (69.1%; 83.7%)	62.4% (54.5%; 71.4%)	44.6% (36.5%; 54.6%)	43.5% (35.2%; 53.8%)	39.3% (30.8%; 50.3%)	45.9% (33.2%; 63.5%)
		IV	60	60.8% (49.5%; 74.8%)	38.6% (27.8%; 53.6%)	30.0% (20.0%; 44.8%)	24.1% (14.9%; 38.9%)	19.0% (10.6%; 34.0%)	FU<10y
		X/NA	582	41.4% (37.4%; 45.8%)	33.4% (29.6%; 37.8%)	28.5% (24.7%; 32.9%)	27.6% (23.7%; 32.2%)	26.4% (22.2%; 31.4%)	23.7% (17.7%; 31.6%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.3. Ovarian cancer survival by type and stage: number at risk and net survival probabilities, 2013-2022

type	grade	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
				Net Survival Probability, 2013-2022					
Ovary		All	7,678	78.5% (77.5%; 79.5%)	67.2% (66.1%; 68.3%)	57.9% (56.7%; 59.1%)	50.9% (49.6%; 52.2%)	45.5% (44.2%; 46.9%)	34.7% (32.5%; 36.9%)
		I	1,554	97.4% (96.4%; 98.4%)	95.8% (94.4%; 97.2%)	94.1% (92.4%; 95.9%)	92.0% (89.9%; 94.1%)	91.4% (89.0%; 93.8%)	88.2% (81.9%; 95.0%)
		II	441	88.5% (85.2%; 91.8%)	82.4% (78.4%; 86.5%)	78.6% (74.1%; 83.3%)	75.1% (70.2%; 80.5%)	68.7% (63.0%; 75.0%)	49.7% (38.0%; 65.0%)
		III	2,546	82.7% (81.1%; 84.2%)	68.4% (66.5%; 70.4%)	56.8% (54.6%; 58.9%)	46.5% (44.3%; 48.8%)	39.3% (37.1%; 41.7%)	22.8% (20.0%; 26.1%)
		IV	2,177	67.0% (64.9%; 69.0%)	50.1% (47.9%; 52.3%)	35.4% (33.3%; 37.7%)	27.2% (25.2%; 29.5%)	20.3% (18.3%; 22.5%)	10.6% (8.4%; 13.3%)
		X/NA	968	58.3% (55.2%; 61.7%)	49.3% (46.0%; 52.8%)	43.5% (40.2%; 47.1%)	38.4% (35.1%; 42.1%)	34.5% (31.1%; 38.3%)	28.3% (23.7%; 33.7%)
Serous carcinoma		All	4,843	82.1% (81.0%; 83.3%)	68.1% (66.7%; 69.6%)	56.3% (54.8%; 57.9%)	46.3% (44.7%; 47.9%)	39.2% (37.6%; 40.9%)	24.6% (22.5%; 27.0%)
		I	401	98.1% (96.1%; 100.0%)	94.6% (91.7%; 97.6%)	92.0% (88.3%; 95.8%)	87.3% (82.7%; 92.2%)	84.5% (79.1%; 90.3%)	82.6% (73.2%; 93.3%)
		II	243	93.1% (89.5%; 96.8%)	87.5% (82.7%; 92.5%)	84.2% (78.8%; 90.0%)	78.4% (72.1%; 85.3%)	71.2% (64.0%; 79.3%)	52.0% (38.3%; 70.6%)
		III	2,033	88.2% (86.6%; 89.7%)	73.7% (71.6%; 75.8%)	61.7% (59.3%; 64.1%)	49.6% (47.1%; 52.2%)	41.6% (39.1%; 44.3%)	21.7% (18.6%; 25.3%)
		IV	1,642	75.8% (73.6%; 78.0%)	57.8% (55.3%; 60.4%)	41.7% (39.1%; 44.4%)	31.6% (29.1%; 34.4%)	23.7% (21.3%; 26.5%)	12.3% (9.6%; 15.7%)
		X/NA	524	61.4% (57.2%; 65.9%)	49.7% (45.3%; 54.5%)	40.6% (36.3%; 45.5%)	32.1% (27.9%; 36.9%)	27.3% (23.3%; 32.1%)	16.5% (11.8%; 22.9%)
	Low-grade	All	790	83.7% (81.0%; 86.5%)	72.1% (68.8%; 75.5%)	62.6% (59.0%; 66.4%)	53.3% (49.5%; 57.4%)	44.6% (40.7%; 48.9%)	35.6% (30.5%; 41.4%)
		I	104	98.9% (95.7%; 102.2%)	95.8% (90.5%; 101.4%)	93.5% (86.9%; 100.6%)	91.1% (83.0%; 100.1%)	89.2% (79.4%; 100.1%)	98.5% (84.9%; 114.3%)
		II	40	N<50	N<50	N<50	N<50	N<50	N<50
		III	314	91.1% (87.7%; 94.7%)	79.9% (75.2%; 85.0%)	67.1% (61.6%; 73.2%)	57.4% (51.5%; 63.9%)	47.2% (41.1%; 54.1%)	33.0% (25.6%; 42.7%)
		IV	222	75.0% (69.4%; 81.2%)	56.0% (49.6%; 63.3%)	45.1% (38.6%; 52.7%)	32.6% (26.3%; 40.3%)	21.5% (16.0%; 28.9%)	14.3% (9.1%; 22.4%)
		X/NA	110	64.8% (56.2%; 74.7%)	56.2% (47.2%; 66.9%)	49.3% (40.3%; 60.4%)	38.6% (29.9%; 49.9%)	33.6% (25.1%; 45.1%)	19.9% (10.6%; 37.6%)
	High-grade	All	3,826	82.2% (80.9%; 83.5%)	67.9% (66.3%; 69.5%)	55.3% (53.5%; 57.1%)	44.8% (43.0%; 46.7%)	38.1% (36.2%; 40.1%)	21.0% (18.3%; 24.0%)
		I	270	98.2% (95.9%; 100.6%)	94.2% (90.5%; 98.0%)	91.5% (86.9%; 96.3%)	86.7% (81.0%; 92.9%)	83.6% (76.8%; 90.9%)	78.9% (65.7%; 94.7%)
		II	187	95.0% (91.3%; 98.9%)	89.2% (83.9%; 94.8%)	85.2% (79.0%; 91.9%)	78.5% (71.1%; 86.7%)	72.7% (64.2%; 82.3%)	50.1% (32.9%; 76.3%)
		III	1,646	87.7% (86.0%; 89.4%)	72.8% (70.5%; 75.2%)	61.0% (58.3%; 63.7%)	48.0% (45.3%; 51.0%)	40.6% (37.7%; 43.6%)	18.2% (14.5%; 22.9%)

type	grade	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Net Survival Probability, 2013-2022									
		IV	1,361	75.9% (73.6%; 78.4%)	58.5% (55.8%; 61.4%)	41.1% (38.3%; 44.1%)	31.4% (28.6%; 34.4%)	24.1% (21.4%; 27.2%)	11.0% (8.0%; 15.3%)
		X/NA	362	62.6% (57.6%; 68.0%)	50.3% (45.0%; 56.1%)	39.8% (34.6%; 45.7%)	30.9% (26.0%; 36.8%)	26.3% (21.5%; 32.1%)	14.0% (9.0%; 21.8%)
	Unspecified	All	227	75.2% (69.5%; 81.3%)	58.4% (52.0%; 65.6%)	51.4% (44.9%; 58.9%)	44.6% (38.1%; 52.3%)	37.9% (31.5%; 45.6%)	26.0% (19.7%; 34.3%)
		I	27	N<50	N<50	N<50	N<50	N<50	N<50
		II	16	N<50	N<50	N<50	N<50	N<50	N<50
		III	73	86.5% (78.6%; 95.3%)	66.5% (56.1%; 78.9%)	54.3% (43.4%; 67.9%)	46.5% (35.8%; 60.5%)	38.9% (28.6%; 52.8%)	21.3% (12.7%; 35.7%)
		IV	59	74.9% (64.2%; 87.4%)	48.2% (36.6%; 63.6%)	40.8% (29.5%; 56.5%)	32.9% (21.9%; 49.6%)	24.4% (14.9%; 40.0%)	19.5% (10.1%; 37.4%)
		X/NA	52	45.1% (33.1%; 61.6%)	31.4% (20.6%; 47.8%)	27.8% (17.4%; 44.2%)	26.5% (16.2%; 43.3%)	21.5% (12.0%; 38.6%)	20.4% (10.3%; 40.4%)
Mucinous carcinoma		All	543	82.3% (79.0%; 85.7%)	76.9% (73.1%; 80.9%)	74.0% (69.9%; 78.3%)	72.6% (68.3%; 77.1%)	70.3% (65.6%; 75.3%)	66.9% (60.0%; 74.5%)
		I	339	98.1% (96.2%; 100.1%)	97.3% (94.6%; 100.0%)	97.4% (94.3%; 100.6%)	95.7% (92.0%; 99.6%)	95.3% (91.0%; 99.8%)	98.8% (92.2%; 106.0%)
		II	27	N<50	N<50	N<50	N<50	N<50	N<50
		III	70	56.5% (45.8%; 69.7%)	37.8% (27.7%; 51.5%)	31.9% (22.1%; 45.9%)	30.7% (20.9%; 45.0%)	29.5% (19.7%; 44.3%)	21.0% (10.9%; 40.5%)
		IV	65	39.5% (29.2%; 53.4%)	26.8% (17.8%; 40.4%)	16.1% (9.0%; 28.7%)	14.3% (7.7%; 26.8%)	12.0% (5.9%; 24.6%)	FU<10y
		X/NA	42	N<50	N<50	N<50	N<50	N<50	N<50
Endometrioid carcinoma		All	517	94.3% (92.0%; 96.7%)	90.8% (87.8%; 93.9%)	89.1% (85.6%; 92.8%)	86.1% (82.0%; 90.5%)	83.8% (79.1%; 88.7%)	80.5% (66.5%; 97.3%)
		I	312	100.2% (98.7%; 101.7%)	98.3% (95.6%; 101.0%)	97.9% (94.5%; 101.4%)	98.0% (93.9%; 102.2%)	98.4% (93.8%; 103.3%)	97.4% (78.1%; 121.5%)
		II	59	95.2% (88.9%; 102.0%)	92.2% (83.9%; 101.3%)	92.3% (82.8%; 102.9%)	87.2% (75.3%; 101.0%)	81.1% (66.3%; 99.3%)	70.0% (40.5%; 121.1%)
		III	75	84.0% (75.6%; 93.4%)	74.3% (64.2%; 85.9%)	65.9% (54.7%; 79.2%)	51.9% (40.2%; 67.0%)	47.4% (35.7%; 62.8%)	41.2% (27.3%; 62.2%)
		IV	34	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	37	N<50	N<50	N<50	N<50	N<50	N<50
Clear-cell carcinoma		All	353	87.1% (83.4%; 90.9%)	80.4% (76.1%; 85.1%)	74.0% (69.0%; 79.3%)	73.3% (68.0%; 78.9%)	69.5% (63.7%; 75.8%)	61.5% (50.8%; 74.5%)
		I	199	98.3% (95.9%; 100.7%)	97.7% (94.6%; 100.9%)	94.4% (90.0%; 99.0%)	93.6% (88.6%; 98.9%)	92.3% (86.3%; 98.6%)	83.0% (68.7%; 100.2%)
		II	29	N<50	N<50	N<50	N<50	N<50	N<50

type	grade	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
				Net Survival Probability, 2013-2022					
		III	63	78.7% (68.9%; 89.9%)	56.9% (45.3%; 71.5%)	45.5% (33.8%; 61.2%)	46.4% (34.5%; 62.5%)	32.6% (21.4%; 49.7%)	19.1% (7.6%; 47.9%)
		IV	37	N<50	N<50	N<50	N<50	N<50	N<50
		X/NA	25	N<50	N<50	N<50	N<50	N<50	N<50
Adenocarcinoma		All	318	36.2% (31.1%; 42.0%)	27.7% (23.0%; 33.4%)	20.9% (16.5%; 26.4%)	18.1% (13.8%; 23.6%)	13.2% (9.4%; 18.4%)	10.3% (6.4%; 16.7%)
		I	12	N<50	N<50	N<50	N<50	N<50	N<50
		II	1	N<50	N<50	N<50	N<50	N<50	N<50
		III	65	42.6% (32.0%; 56.8%)	35.7% (25.5%; 50.1%)	26.9% (17.5%; 41.3%)	25.0% (15.7%; 39.7%)	20.8% (12.2%; 35.6%)	17.4% (8.6%; 35.5%)
		IV	176	33.3% (26.9%; 41.2%)	23.3% (17.7%; 30.8%)	13.5% (9.0%; 20.4%)	10.6% (6.5%; 17.3%)	4.8% (2.2%; 10.5%)	FU<10y
		X/NA	64	26.2% (17.2%; 40.0%)	18.4% (10.6%; 31.9%)	19.5% (11.2%; 33.7%)	17.0% (9.0%; 32.0%)	12.7% (5.9%; 27.2%)	10.1% (4.0%; 25.6%)
Other and unspecified		All	1,114	62.8% (59.9%; 65.8%)	54.5% (51.4%; 57.7%)	48.0% (44.9%; 51.4%)	47.0% (43.7%; 50.5%)	45.7% (42.2%; 49.5%)	41.4% (35.4%; 48.5%)
		I	293	92.5% (89.2%; 95.9%)	91.8% (88.1%; 95.6%)	89.2% (84.6%; 94.0%)	87.2% (81.9%; 92.9%)	89.1% (83.6%; 94.9%)	79.1% (65.7%; 95.1%)
		II	82	74.2% (64.7%; 85.1%)	65.2% (54.7%; 77.6%)	62.4% (51.4%; 75.8%)	63.9% (52.2%; 78.2%)	64.8% (52.5%; 80.1%)	54.7% (31.2%; 95.9%)
		III	240	55.0% (48.9%; 61.9%)	42.8% (36.6%; 49.9%)	30.5% (24.7%; 37.6%)	29.6% (23.7%; 37.0%)	26.9% (20.9%; 34.6%)	31.6% (22.7%; 43.9%)
		IV	223	39.8% (33.8%; 47.0%)	23.6% (18.5%; 30.2%)	13.7% (9.7%; 19.5%)	12.2% (8.3%; 17.9%)	10.0% (6.4%; 15.7%)	FU<10y
		X/NA	276	53.1% (47.2%; 59.6%)	46.7% (40.8%; 53.5%)	43.9% (37.8%; 50.9%)	43.4% (37.1%; 50.6%)	41.5% (34.8%; 49.6%)	37.6% (27.6%; 51.2%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Belgian Cancer Registry

5.1. Ovarian cancer survival trends: by tumour stage

5.1.1. Ovarian cancer survival trends by stage: number at risk and net survival probabilities, 2008-2022

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	All	4,117	76.9% (75.5%; 78.2%)	54.5% (52.9%; 56.2%)	43.1% (41.4%; 44.8%)
	I	669	96.8% (95.2%; 98.5%)	91.3% (88.5%; 94.2%)	89.1% (85.7%; 92.8%)
	II	231	87.4% (82.9%; 92.2%)	70.2% (63.8%; 77.2%)	61.7% (54.6%; 69.7%)
	III	1,134	82.7% (80.4%; 85.1%)	54.7% (51.7%; 57.9%)	36.4% (33.5%; 39.5%)
	IV	827	65.6% (62.4%; 69.1%)	35.9% (32.6%; 39.6%)	23.1% (20.2%; 26.6%)
	X/NA	1,256	66.4% (63.8%; 69.2%)	44.1% (41.3%; 47.2%)	34.4% (31.5%; 37.5%)
2013-2017	All	3,887	78.3% (76.9%; 79.7%)	57.7% (56.1%; 59.4%)	45.3% (43.6%; 47.1%)
	I	751	97.5% (96.1%; 98.9%)	93.3% (91.0%; 95.7%)	90.3% (87.2%; 93.5%)
	II	220	89.3% (85.0%; 93.9%)	76.5% (70.4%; 83.1%)	65.7% (58.6%; 73.6%)
	III	1,308	83.4% (81.3%; 85.6%)	56.0% (53.2%; 59.0%)	38.8% (36.0%; 41.8%)
	IV	978	65.1% (62.1%; 68.2%)	36.3% (33.2%; 39.6%)	21.0% (18.4%; 23.9%)
	X/NA	634	61.4% (57.5%; 65.5%)	45.4% (41.4%; 49.8%)	36.1% (32.1%; 40.7%)
2018-2022	All	3,792	78.7% (77.3%; 80.1%)	57.9% (56.1%; 59.7%)	46.0% (43.7%; 48.3%)
	I	803	97.3% (95.9%; 98.8%)	94.9% (92.3%; 97.5%)	92.9% (89.0%; 96.9%)
	II	221	87.7% (82.9%; 92.6%)	81.3% (75.0%; 88.1%)	72.9% (62.7%; 84.7%)
	III	1,238	81.9% (79.6%; 84.2%)	57.4% (54.2%; 60.7%)	40.2% (36.4%; 44.4%)

Period	Stage	Net Survival Probability					
		N at risk	1-y	(95%CI)	3-y (95%CI)	5-y (95%CI)
	IV	1,199	68.5%	(65.8%; 71.3%)	34.3% (31.4%; 37.6%)	19.8% (16.7%; 23.6%)
	X/NA	334	52.6%	(47.3%; 58.5%)	40.1% (34.7%; 46.5%)	31.5% (25.6%; 38.7%)

5.2. Ovarian cancer survival trends: by tumour type and tumour stage

5.2.1. Ovarian cancer survival trends by type and stage: number at risk and net survival probabilities, 2008-2022

Period	type	grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
					Net Survival Probability		
2008-2012	Serous carcinoma		**All**	2,361	83.0% (81.4%; 84.6%)	56.7% (54.6%; 58.9%)	40.8% (38.7%; 43.0%)
			I	219	95.4% (92.2%; 98.8%)	91.4% (86.5%; 96.6%)	88.2% (82.0%; 95.0%)
			II	142	88.2% (82.5%; 94.2%)	68.5% (60.4%; 77.6%)	57.7% (49.1%; 67.9%)
			III	842	88.3% (86.0%; 90.7%)	59.7% (56.3%; 63.3%)	39.0% (35.6%; 42.7%)
			IV	525	77.3% (73.7%; 81.2%)	44.4% (40.1%; 49.1%)	27.4% (23.7%; 31.8%)
			X/NA	633	75.1% (71.6%; 78.7%)	48.2% (44.2%; 52.5%)	33.9% (30.2%; 38.2%)
		Low-grade	**All**	1,431	83.0% (81.0%; 85.1%)	55.8% (53.1%; 58.6%)	39.4% (36.8%; 42.3%)
			I	113	94.5% (89.7%; 99.5%)	90.7% (84.1%; 97.8%)	82.0% (73.4%; 91.7%)
			II	89	87.0% (79.6%; 95.1%)	68.6% (58.6%; 80.3%)	60.1% (49.4%; 73.1%)
			III	552	88.4% (85.6%; 91.4%)	58.9% (54.7%; 63.5%)	37.1% (33.0%; 41.7%)
			IV	306	79.4% (74.8%; 84.2%)	44.6% (39.1%; 50.9%)	27.9% (23.1%; 33.8%)
			X/NA	371	73.5% (69.0%; 78.3%)	46.5% (41.4%; 52.2%)	34.2% (29.4%; 39.9%)
		High-grade	**All**	220	90.4% (86.2%; 94.7%)	62.8% (56.3%; 70.0%)	49.2% (42.6%; 56.9%)
			I	12	N<50	N<50	N<50
			II	2	N<50	N<50	N<50
			III	83	92.7% (86.7%; 99.0%)	64.7% (54.7%; 76.5%)	50.9% (40.7%; 63.7%)
			IV	73	82.1% (73.4%; 91.9%)	50.2% (39.5%; 63.7%)	36.1% (26.1%; 49.9%)
			X/NA	50	95.6% (89.1%; 102.4%)	71.0% (58.4%; 86.3%)	53.9% (40.7%; 71.4%)
		Unspecified	**All**	710	80.6% (77.6%; 83.7%)	56.6% (52.8%; 60.7%)	40.9% (37.1%; 45.1%)
			I	94	95.9% (91.0%; 101.1%)	91.8% (84.1%; 100.1%)	94.4% (84.9%; 105.0%)

Period	type	grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	51	89.6% (81.0%; 99.2%)	68.9% (56.1%; 84.6%)	53.7% (40.4%; 71.3%)
			III	207	86.3% (81.4%; 91.4%)	59.7% (53.0%; 67.3%)	39.2% (32.7%; 47.0%)
			IV	146	70.7% (63.4%; 78.8%)	41.1% (33.5%; 50.5%)	22.1% (16.0%; 30.5%)
			X/NA	212	73.0% (67.1%; 79.5%)	45.8% (39.2%; 53.4%)	28.7% (22.8%; 36.1%)
	Mucinous carcinoma		All	334	78.9% (74.5%; 83.6%)	66.8% (61.5%; 72.6%)	62.7% (57.0%; 69.0%)
			I	161	98.4% (95.7%; 101.3%)	94.5% (89.3%; 100.0%)	91.7% (85.0%; 98.9%)
			II	13	N<50	N<50	N<50
			III	43	N<50	N<50	N<50
			IV	39	N<50	N<50	N<50
			X/NA	78	71.8% (62.3%; 82.9%)	50.7% (40.2%; 63.9%)	45.8% (35.2%; 59.6%)
	Endometrioid carcinoma		All	252	94.3% (91.1%; 97.6%)	80.8% (75.4%; 86.5%)	70.7% (64.4%; 77.7%)
			I	111	100.6% (98.9%; 102.5%)	94.8% (89.1%; 101.0%)	91.3% (83.6%; 99.7%)
			II	20	N<50	N<50	N<50
			III	49	N<50	N<50	N<50
			IV	20	N<50	N<50	N<50
			X/NA	52	87.6% (78.7%; 97.5%)	76.1% (64.6%; 89.7%)	60.7% (47.6%; 77.4%)
	Clear-cell carcinoma		All	133	89.4% (84.0%; 95.2%)	75.0% (67.3%; 83.6%)	71.3% (62.7%; 81.1%)
			I	59	100.1% (96.8%; 103.5%)	93.9% (85.5%; 103.1%)	99.4% (90.6%; 109.1%)
			II	9	N<50	N<50	N<50
			III	28	N<50	N<50	N<50
			IV	13	N<50	N<50	N<50
			X/NA	24	N<50	N<50	N<50
	Adenocarcinoma		All	497	49.0% (44.7%; 53.8%)	24.9% (21.2%; 29.3%)	19.3% (15.9%; 23.4%)
			I	28	N<50	N<50	N<50

Period	type	grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	12	N<50	N<50	N<50
			III	84	60.8% (50.9%; 72.5%)	31.1% (22.3%; 43.3%)	22.2% (14.6%; 33.8%)
			IV	136	39.7% (32.0%; 49.1%)	15.5% (10.2%; 23.3%)	9.7% (5.6%; 16.6%)
			X/NA	237	43.5% (37.5%; 50.5%)	19.2% (14.5%; 25.4%)	14.8% (10.6%; 20.7%)
	Other and unspecified		All	540	63.4% (59.3%; 67.8%)	47.4% (43.0%; 52.2%)	43.2% (38.3%; 48.9%)
			I	91	92.6% (86.9%; 98.7%)	83.4% (75.0%; 92.7%)	83.1% (73.6%; 93.9%)
			II	35	N<50	N<50	N<50
			III	88	66.7% (57.3%; 77.6%)	39.4% (30.1%; 51.7%)	30.1% (21.4%; 42.4%)
			IV	94	40.7% (31.7%; 52.2%)	17.4% (10.8%; 28.1%)	11.9% (5.4%; 26.3%)
			X/NA	232	56.6% (50.3%; 63.6%)	45.0% (38.4%; 52.7%)	42.9% (35.4%; 52.1%)
2013-2017	Serous carcinoma		All	2,452	82.2% (80.6%; 83.8%)	56.8% (54.7%; 58.9%)	39.5% (37.4%; 41.7%)
			I	202	97.8% (95.1%; 100.6%)	91.4% (86.5%; 96.7%)	82.1% (75.2%; 89.7%)
			II	129	91.4% (86.2%; 96.9%)	83.2% (76.1%; 91.0%)	69.2% (60.5%; 79.2%)
			III	1,042	89.1% (87.1%; 91.2%)	61.1% (58.0%; 64.4%)	41.4% (38.2%; 44.8%)
			IV	725	74.0% (70.7%; 77.4%)	42.7% (39.1%; 46.7%)	24.2% (21.1%; 27.8%)
			X/NA	354	66.1% (61.1%; 71.4%)	43.1% (37.9%; 49.1%)	30.1% (25.2%; 35.9%)
		Low-grade	All	558	82.9% (79.7%; 86.3%)	58.6% (54.4%; 63.1%)	40.3% (36.0%; 45.0%)
			I	62	98.5% (94.1%; 103.2%)	90.4% (81.5%; 100.4%)	86.1% (74.2%; 99.8%)
			II	28	N<50	N<50	N<50
			III	226	92.4% (88.6%; 96.4%)	62.9% (56.4%; 70.1%)	42.6% (36.1%; 50.2%)
			IV	152	72.1% (65.1%; 79.8%)	41.2% (33.9%; 50.2%)	18.4% (13.0%; 26.0%)
			X/NA	90	68.0% (58.7%; 78.7%)	50.3% (40.4%; 62.6%)	33.4% (24.3%; 46.1%)
		High-grade	All	1,694	82.0% (80.0%; 83.9%)	56.2% (53.7%; 58.8%)	38.9% (36.5%; 41.6%)
			I	114	98.4% (95.0%; 101.9%)	92.1% (85.6%; 99.1%)	81.2% (71.9%; 91.7%)

Period	type	grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	86	96.0% (91.0%; 101.2%)	86.3% (77.9%; 95.6%)	71.9% (61.2%; 84.3%)
			III	743	88.4% (86.0%; 90.9%)	61.3% (57.6%; 65.2%)	41.2% (37.6%; 45.3%)
			IV	518	74.5% (70.7%; 78.5%)	43.3% (39.0%; 48.1%)	25.8% (22.0%; 30.2%)
			X/NA	233	64.8% (58.7%; 71.5%)	40.2% (34.0%; 47.6%)	28.3% (22.6%; 35.5%)
		Unspecified	All	200	81.8% (76.3%; 87.6%)	56.2% (49.3%; 64.1%)	42.0% (35.0%; 50.2%)
			I	26	N<50	N<50	N<50
			II	15	N<50	N<50	N<50
			III	73	86.5% (78.6%; 95.3%)	54.3% (43.4%; 67.9%)	38.9% (28.6%; 52.8%)
			IV	55	74.5% (63.5%; 87.5%)	41.4% (29.8%; 57.6%)	26.2% (16.1%; 42.5%)
			X/NA	31	N<50	N<50	N<50
	Mucinous carcinoma		All	282	81.8% (77.3%; 86.6%)	70.2% (64.7%; 76.2%)	66.2% (60.3%; 72.6%)
			I	162	97.1% (94.2%; 100.1%)	95.3% (91.2%; 99.5%)	91.8% (86.4%; 97.5%)
			II	16	N<50	N<50	N<50
			III	44	N<50	N<50	N<50
			IV	32	N<50	N<50	N<50
			X/NA	28	N<50	N<50	N<50
	Endometrioid carcinoma		All	270	92.5% (89.0%; 96.2%)	86.0% (81.1%; 91.2%)	81.7% (75.8%; 88.1%)
			I	162	99.1% (96.5%; 101.7%)	95.1% (90.2%; 100.2%)	96.3% (90.5%; 102.5%)
			II	25	N<50	N<50	N<50
			III	43	N<50	N<50	N<50
			IV	13	N<50	N<50	N<50
			X/NA	27	N<50	N<50	N<50
	Clear-cell carcinoma		All	187	87.9% (83.1%; 93.1%)	77.0% (70.5%; 84.0%)	74.2% (67.0%; 82.1%)
			I	111	100.4% (98.6%; 102.2%)	95.2% (89.7%; 101.0%)	95.2% (88.3%; 102.5%)

Period	type	grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	15	N<50	N<50	N<50
			III	27	N<50	N<50	N<50
			IV	18	N<50	N<50	N<50
			X/NA	16	N<50	N<50	N<50
	Adenocarcinoma		All	161	37.6% (30.7%; 46.1%)	23.4% (17.4%; 31.4%)	14.9% (10.0%; 22.2%)
			I	7	N<50	N<50	N<50
			II	1	N<50	N<50	N<50
			III	36	N<50	N<50	N<50
			IV	78	34.3% (25.1%; 46.9%)	13.8% (7.7%; 24.5%)	6.0% (2.5%; 14.6%)
			X/NA	39	N<50	N<50	N<50
	Other and unspecified		All	541	60.5% (56.4%; 65.0%)	45.2% (40.8%; 49.9%)	42.4% (37.8%; 47.5%)
			I	109	92.3% (86.9%; 98.0%)	89.0% (82.0%; 96.6%)	89.3% (81.1%; 98.3%)
			II	34	N<50	N<50	N<50
			III	116	59.1% (50.6%; 69.0%)	32.0% (24.1%; 42.3%)	27.8% (20.0%; 38.7%)
			IV	112	38.1% (30.0%; 48.4%)	14.9% (9.5%; 23.4%)	10.4% (5.9%; 18.2%)
			X/NA	170	51.8% (44.4%; 60.4%)	43.3% (35.7%; 52.5%)	39.8% (31.7%; 50.1%)
2018-2022	Serous carcinoma		All	2,391	82.1% (80.5%; 83.8%)	55.6% (53.3%; 58.0%)	39.4% (36.6%; 42.4%)
			I	199	98.3% (95.7%; 101.1%)	92.4% (87.0%; 98.2%)	89.7% (82.0%; 98.0%)
			II	114	95.0% (90.2%; 100.0%)	85.2% (77.1%; 94.2%)	74.0% (61.1%; 89.5%)
			III	991	87.1% (84.9%; 89.4%)	62.1% (58.6%; 65.8%)	41.9% (37.5%; 46.8%)
			IV	917	77.2% (74.4%; 80.1%)	40.4% (36.8%; 44.2%)	24.5% (20.8%; 29.0%)
			X/NA	170	51.7% (44.4%; 60.1%)	35.7% (28.4%; 44.8%)	20.9% (14.3%; 30.5%)
		Low-grade	All	232	85.5% (80.8%; 90.4%)	73.1% (66.7%; 80.0%)	60.2% (51.7%; 70.2%)
			I	42	N<50	N<50	N<50

Period	type	grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			II	12	N<50	N<50	N<50
			III	88	87.8% (80.8%; 95.5%)	79.5% (70.0%; 90.2%)	63.1% (49.7%; 80.1%)
			IV	70	81.5% (72.5%; 91.5%)	53.2% (41.1%; 68.8%)	37.7% (24.4%; 58.1%)
			X/NA	20	N<50	N<50	N<50
		High-grade	All	2,132	82.4% (80.7%; 84.2%)	54.1% (51.7%; 56.7%)	37.5% (34.6%; 40.6%)
			I	156	98.0% (94.9%; 101.3%)	90.8% (84.4%; 97.7%)	87.8% (78.9%; 97.6%)
			II	101	94.3% (88.9%; 99.9%)	84.1% (75.3%; 94.0%)	74.2% (60.6%; 90.9%)
			III	903	87.1% (84.7%; 89.5%)	60.3% (56.5%; 64.2%)	39.4% (34.8%; 44.6%)
			IV	843	76.8% (73.9%; 79.9%)	39.3% (35.7%; 43.4%)	23.8% (20.0%; 28.4%)
			X/NA	129	58.6% (50.4%; 68.3%)	39.3% (30.7%; 50.2%)	21.5% (14.0%; 33.0%)
		Unspecified	All	27	N<50	N<50	N<50
			I	1	N<50	N<50	N<50
			II	1	N<50	N<50	N<50
			IV	4	N<50	N<50	N<50
			X/NA	21	N<50	N<50	N<50
	Mucinous carcinoma		All	261	82.8% (78.1%; 87.8%)	78.5% (72.7%; 84.8%)	74.7% (66.0%; 84.6%)
			I	177	99.0% (96.5%; 101.6%)	99.4% (94.7%; 104.3%)	100.6% (93.4%; 108.4%)
			II	11	N<50	N<50	N<50
			III	26	N<50	N<50	N<50
			IV	33	N<50	N<50	N<50
			X/NA	14	N<50	N<50	N<50
	Endometrioid carcinoma		All	247	96.3% (93.3%; 99.3%)	93.0% (88.3%; 98.0%)	85.8% (78.2%; 94.3%)
			I	150	101.4% (100.1%; 102.7%)	101.3% (97.0%; 105.9%)	99.8% (91.2%; 109.3%)
			II	34	N<50	N<50	N<50

The header spanning "Net Survival Probability" covers the 1-y, 3-y, and 5-y columns.

33

Period	type	grade	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
			III	32	N<50	N<50	N<50
			IV	21	N<50	N<50	N<50
			X/NA	10	N<50	N<50	N<50
	Clear-cell carcinoma		All	166	86.1% (80.7%; 91.8%)	70.5% (62.9%; 78.9%)	60.9% (50.9%; 72.8%)
			I	88	95.6% (90.8%; 100.6%)	94.1% (87.6%; 101.1%)	85.9% (74.9%; 98.6%)
			II	14	N<50	N<50	N<50
			III	36	N<50	N<50	N<50
			IV	19	N<50	N<50	N<50
			X/NA	9	N<50	N<50	N<50
	Adenocarcinoma		All	157	34.7% (27.8%; 43.3%)	17.5% (11.8%; 25.9%)	10.2% (5.3%; 19.7%)
			I	5	N<50	N<50	N<50
			III	29	N<50	N<50	N<50
			IV	98	32.5% (24.3%; 43.4%)	13.1% (7.3%; 23.5%)	2.6% (0.6%; 11.7%)
			X/NA	25	N<50	N<50	N<50
	Other and unspecified		All	573	64.9% (60.9%; 69.1%)	50.5% (46.0%; 55.5%)	50.1% (45.2%; 55.6%)
			I	184	92.6% (88.5%; 96.9%)	88.5% (82.2%; 95.4%)	86.9% (79.3%; 95.2%)
			II	48	N<50	N<50	N<50
			III	124	51.2% (42.8%; 61.2%)	28.5% (20.7%; 39.3%)	27.3% (19.3%; 38.7%)
			IV	111	41.6% (33.2%; 52.1%)	12.3% (7.2%; 21.2%)	10.0% (4.9%; 20.5%)
			X/NA	106	55.1% (46.1%; 65.8%)	44.7% (35.5%; 56.4%)	46.1% (36.6%; 58.2%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Ovarian cancer mortality: by region

6.1.1. Ovarian cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Belgium	0	0	0	0	0	2	1	2	8	9	26	30	42	74	81	95	98	83	40	11	602	9.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.3]	[0.5]	[2.1]	[2.4]	[6.7]	[7.5]	[11.3]	[22.7]	[27.3]	[44.5]	[53.0]	[61.4]	[60.4]	[57.2]	[10.3]	(8.5; 10.0)
Brussels	0	0	0	0	0	0	0	0	1	3	4	1	1	3	6	8	5	4	3	1	40	7.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[7.5]	[10.8]	[3.0]	[3.4]	[12.2]	[27.8]	[49.2]	[36.5]	[39.4]	[52.3]	[51.1]	[6.4]	(5.4; 10.4)
Flanders	0	0	0	0	0	0	1	2	3	4	15	19	27	55	47	60	68	57	27	7	392	9.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.0]	[1.4]	[1.9]	[6.6]	[7.9]	[12.2]	[28.5]	[27.0]	[45.0]	[58.6]	[67.1]	[67.3]	[62.3]	[11.7]	(8.9; 10.9)
Wallonia	0	0	0	0	0	2	0	0	4	2	7	10	14	16	28	27	25	22	10	3	170	8.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[0.0]	[0.0]	[3.5]	[1.6]	[5.6]	[7.8]	[11.6]	[14.7]	[27.8]	[42.4]	[45.3]	[54.9]	[49.0]	[49.7]	[9.1]	(7.1; 9.7)

7.1. Ovarian cancer mortality trends: by region

7.1.1. Ovarian cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	**N**	682	669	663	709	668	687	696	654	678	616	601	665	565	606	574	611	585	602		
	CR	12.8	12.5	12.4	13.1	12.3	12.5	12.6	11.7	12.1	10.9	10.6	11.7	9.9	10.5	9.9	10.5	10.0	10.3		
	ESR2013	13.0	12.5	12.4	13.0	12.0	12.2	12.2	11.2	11.5	10.4	10.1	11.1	9.3	9.7	9.1	9.6	9.2	9.3	-2.3 (-2.7; -1.9)	2004-2021
Brussels	**N**	66	38	56	55	60	56	55	54	56	45	54	51	41	37	53	35	36	40		
	CR	12.7	7.3	10.6	10.3	11.1	10.1	9.8	9.4	9.6	7.6	9.0	8.5	6.7	6.1	8.7	5.7	5.8	6.4		
	ESR2013	12.9	7.4	11.8	11.3	12.0	11.6	10.7	10.6	10.7	8.7	10.3	10.3	7.8	7.2	10.7	6.7	7.3	7.9	-2.5 (-4.0; -0.9)	2004-2021
Flanders	**N**	386	430	396	427	398	412	418	388	394	369	370	376	360	364	352	386	355	392		
	CR	12.7	14.0	12.9	13.8	12.7	13.1	13.2	12.2	12.3	11.4	11.4	11.5	11.0	11.0	10.6	11.6	10.6	11.7		
	ESR2013	12.7	13.9	12.7	13.4	12.1	12.4	12.4	11.3	11.2	10.5	10.5	10.4	9.8	9.6	9.1	10.0	9.1	9.9	-2.3 (-2.8; -1.9)	2004-2021
Wallonia	**N**	230	201	211	227	210	219	223	212	228	202	177	238	164	205	169	190	194	170		
	CR	13.2	11.5	12.0	12.8	11.8	12.3	12.4	11.7	12.5	11.0	9.6	12.9	8.9	11.1	9.1	10.2	10.4	9.1		
	ESR2013	13.4	11.5	12.0	12.7	12.0	12.0	12.2	11.1	12.3	10.7	9.1	12.6	8.6	10.6	8.6	9.5	9.8	8.4	-2.2 (-3.1; -1.3)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024